Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1,533 pregnancies in Czech Republic.
Pregnancy in patients with multiple sclerosis (MS) requires special care, particularly with regard to decision-making regarding disease-modifying disease (DMD) treatment and counselling regarding the period of conception, pregnancy and the postpartum period. This study aims to analyse the impact of pregnancy, childbirth or miscarriage on the course of multiple sclerosis...
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia
he emergence of the novel coronavirus COVID-19 has raised concerns about the course of this disease in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the incidence, severity, and risk factors for a more severe course of COVID-19 among patients with MS and NMOSD...
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
Although more than a dozen disease-modifying treatments (DMTs) are available for relapsing forms of multiple sclerosis (MS), treatment interruptions, switches, and discontinuations are common challenges. This study focuses on describing treatment interruptions and discontinuations within the Big Multiple Sclerosis Data Network. Under the leadership of Prof. Jan Hillert from Sweden's Karolinska Institutet, data from five clinical registries covering a 20-year period...
Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. After the first demyelinating event, well-established drugs...
What data does the national registry of patients with multiple sclerosis ReMuS offer?
In a review article in the professional journal Neurologie pro praxi the professional guarantor of the ReMuS registry focused on presenting the ReMuS registry and, in particular, the range of data it contains. The article also provides insight into the representation of patients in individual MS centers across the Czech Republic, the development of the use of highly effective medicinal products, and the critically important area of...
Multiple Sclerosis Patient Registry ReMuS - the importance of data in chronic diseases
A new article in the professional journal Remedia provides insights into what can be found in the data of the Multiple Sclerosis Patient Registry ReMuS after six years of operation, as well as in the real clinical practice of the Czech Republic. Since its inception, records of...
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
Proper management of multiple sclerosis treatment requires feedback from clinical practice, which is provided by registries. This article focuses on introducing the Czech national multiple sclerosis registry, ReMuS, and examines the availability and use of disease-modifying drugs ...
How We Have Progressed Over Five Years of the ReMuS Registry's Existence
In its five years of existence, the Czech national registry of multiple sclerosis patients, ReMuS, has become an invaluable source of data for both clinical practice and research. This article provides an overview of how the registry has developed since its inception in 2013...
Multiple sclerosis registries in Europe - Updated overview
In 2018, an updated mapping of multiple sclerosis (MS) registries in Europe was conducted, building on a previous survey from 2014. This survey includes 19 registries, mostly from Europe, and provides detailed information on the organization, data collection methods, quality control mechanisms, and funding of these registries...
A comparison of efficacy of subcutaneous interferon β-1a 44 μg, dimethyl fumarate and fingolimod in the real-life clinical practise – a multicenter observational study
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease affecting the central nervous system. Interferon (IFN) β-1a 44 μg, dimethyl fumarate (DMF), and fingolimod are established medications for the treatment of relapsing-remitting MS (RR MS). The aim of this project, which includes an analysis of data from the ReMuS registry, was...